{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:34:17Z","timestamp":1780497257160,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:00:00Z","timestamp":1428451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:00:00Z","timestamp":1428451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (<jats:italic>p<\/jats:italic> = 0.010) or TBIL &gt; 1 mg\/dL (<jats:italic>p<\/jats:italic> = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.<\/jats:p>","DOI":"10.1038\/srep09772","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T15:10:36Z","timestamp":1429542636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis"],"prefix":"10.1038","volume":"5","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-ya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-quan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-ming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,8]]},"reference":[{"key":"BFsrep09772_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan, M. M. & Gershwin, M. E. Primary biliary cirrhosis. N. Engl. J. Med. 353, 1261-1273 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep09772_CR2","doi-asserted-by":"crossref","unstructured":"Selmi, C., Bowlus, C. L., Gershwin, M. E. & Coppel, R. L. Primary biliary cirrhosis. The Lancet. 377, 1600-1609.","DOI":"10.1016\/S0140-6736(10)61965-4"},{"key":"BFsrep09772_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology 50, 291-308 (2009).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon, R. E., Balkau, B., Eschw\u00e8ge, E. & Poupon, R. A. Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis. N. Engl. J. Med. 324, 1548-1554 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep09772_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","volume":"110","author":"KD Lindor","year":"1996","unstructured":"Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M. & Dickson, E. R. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110, 1515-1518 (1996).","journal-title":"Gastroenterology"},{"key":"BFsrep09772_CR6","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/hep.510290603","volume":"29","author":"RE Poupon","year":"1999","unstructured":"Poupon, R. E., Bonnand, A. M., Chretien, Y. & Poupon, R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29, 1668-1671 (1999).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48, 871-877 (2008).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi, T. et al. Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis. Am. J. Gastroenterol 105, 2186-2194 (2010).","journal-title":"Am. J. Gastroenterol"},{"key":"BFsrep09772_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares, A., Caballeria, L. & Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130, 715-720 (2006).","journal-title":"Gastroenterology"},{"key":"BFsrep09772_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EMM Kuiper","year":"2009","unstructured":"Kuiper, E. M. M. et al. Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid. Gastroenterology 136, 1281-1287 (2009).","journal-title":"Gastroenterology"},{"key":"BFsrep09772_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/hep.26322","volume":"58","author":"LN Zhang","year":"2013","unstructured":"Zhang, L. N. et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 58, 264-272 (2013).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","volume":"41","author":"N Azemoto","year":"2011","unstructured":"Azemoto, N. et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatology Research. 41, 310-317 (2011).","journal-title":"Hepatology Research."},{"key":"BFsrep09772_CR13","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot, C., Chazouilleres, O. & Poupon, R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J. Hepatol. 55, 1361-1367 (2011).","journal-title":"J. Hepatol."},{"key":"BFsrep09772_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.23637","volume":"52","author":"MG Silveira","year":"2010","unstructured":"Silveira, M. G. et al. American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 52, 349-359 (2010).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","volume":"44","author":"N Azemoto","year":"2009","unstructured":"Azemoto, N. et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J. Gastroenterol. 44, 630-634 (2009).","journal-title":"J. Gastroenterol."},{"key":"BFsrep09772_CR16","doi-asserted-by":"crossref","first-page":"18911","DOI":"10.1016\/S0021-9258(18)37369-1","volume":"263","author":"SR Carlsson","year":"1988","unstructured":"Carlsson, S. R., Roth, J., Piller, F. & Fukuda, M. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan. J. Biol. Chem. 263, 18911-18919 (1988).","journal-title":"J. Biol. Chem."},{"key":"BFsrep09772_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1600-0854.2005.00337.x","volume":"6","author":"E-L Eskelinen","year":"2005","unstructured":"Eskelinen, E.-L. et al. Unifying Nomenclature for the Isoforms of the Lysosomal Membrane Protein LAMP-2. Traffic 6, 1058-1061 (2005).","journal-title":"Traffic"},{"key":"BFsrep09772_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/nm.1874","volume":"14","author":"R Kain","year":"2008","unstructured":"Kain, R. et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 14, 1088-1096 (2008).","journal-title":"Nat. Med."},{"key":"BFsrep09772_CR19","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.1016\/S0021-9258(18)31441-8","volume":"268","author":"R Sawada","year":"1993","unstructured":"Sawada, R., Lowe, J. B. & Fukuda, M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. J. Biol. Chem. 268, 12675-12681 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFsrep09772_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/35022595","volume":"406","author":"Y Tanaka","year":"2000","unstructured":"Tanaka, Y. et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902-906 (2000).","journal-title":"Nature"},{"key":"BFsrep09772_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2005.03.009","volume":"22","author":"D Zhou","year":"2005","unstructured":"Zhou, D. et al. Lamp-2a Facilitates MHC Class II Presentation of Cytoplasmic Antigens. Immunity 22, 571-581 (2005).","journal-title":"Immunity"},{"key":"BFsrep09772_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jprot.2013.08.019","volume":"91","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2. J. Proteomics 91, 569-579 (2013).","journal-title":"J. Proteomics"},{"key":"BFsrep09772_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","volume":"32","author":"N Momah","year":"2012","unstructured":"Momah, N., Silveira, M. G., Jorgensen, R., Sinakos, E. & Lindor, K. D. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver International 32, 790-795 (2012).","journal-title":"Liver International"},{"key":"BFsrep09772_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo, P. et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 19, 115-121 (1999).","journal-title":"Liver"},{"key":"BFsrep09772_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","volume":"128","author":"C Corpechot","year":"2005","unstructured":"Corpechot, C. et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128, 297-303 (2005).","journal-title":"Gastroenterology"},{"key":"BFsrep09772_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hep.510290140","volume":"29","author":"AM Bonnand","year":"1999","unstructured":"Bonnand, A. M., Heathcote, E. J., Lindor, K. D. & Poupon, R. E. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29, 39-43 (1999).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/gast.2002.31880","volume":"122","author":"C Corpechot","year":"2002","unstructured":"Corpechot, C., Carrat, F., Poupon, R. & Poupon, R. E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122, 652-658 (2002).","journal-title":"Gastroenterology"},{"key":"BFsrep09772_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/35022604","volume":"406","author":"I Nishino","year":"2000","unstructured":"Nishino, I. et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406, 906-910 (2000).","journal-title":"Nature"},{"key":"BFsrep09772_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1582-4934.2009.00973.x","volume":"15","author":"A Schneede","year":"2011","unstructured":"Schneede, A. et al. Role for LAMP-2 in endosomal cholesterol transport. J. Cell. Mol. Med. 15, 280-295 (2011).","journal-title":"J. Cell. Mol. Med."},{"key":"BFsrep09772_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig, J., Dickson, E. R. & McDonald, G. S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch. A Pathol. Anat. Histol. 379, 103-112 (1978).","journal-title":"Virchows Arch. A Pathol. Anat. Histol."},{"key":"BFsrep09772_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48, 871-877 (2008).","journal-title":"Hepatology"},{"key":"BFsrep09772_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s, A., Caballer\u00eda, L. & Rod\u00e9s, J. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. Gastroenterology 130, 715-720 (2006).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep09772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09772","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T13:40:55Z","timestamp":1672926055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep09772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep09772"],"URL":"https:\/\/doi.org\/10.1038\/srep09772","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,8]]},"assertion":[{"value":"18 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"9772"}}